Gene-expression profiles predict survival of patients with lung adenocarcinoma
Gene-expression profiles predict survival of patients with lung adenocarcinoma
复制标题
DOI：
10.1038/nm733
复制
发表时间：
2002-08-01
期刊：
影响因子：
82.9
通讯作者：
Hanash, S
中科院分区：
文献类型：
--
作者：
Beer, DG;Kardia, SLR;Hanash, S
组织病理学不足以预测肺腺癌的疾病进展和临床结果。在这里，我们展示了基于微阵列分析的基因表达谱可用于预测早期肺腺癌患者的生存。通过单变量Cox分析确定与生存最相关的基因。使用两个相等但独立的训练和测试集，或对所有肿瘤进行“留一”交叉验证分析，基于前50个基因的风险指数确定了低风险和高风险的I期肺腺癌，它们在生存方面存在显着差异。然后使用独立的肺腺癌样本验证该风险指数，预测高风险和低风险组。该指数包括了以前与生存无关的基因。鉴别出一组预测早期肺腺癌患者生存的基因，可以确定可能受益于辅助治疗的高危人群。
Histopathology is insufficient to predict disease progression and clinical outcome in lung adenocarcinoma. Here we show that gene-expression profiles based on microarray analysis can be used to predict patient survival in early-stage lung adenocarcinomas. Genes most related to survival were identified with univariate Cox analysis. Using either two equivalent but independent training and testing sets, or 'leave-one-out' cross-validation analysis with all tumors, a risk index based on the top 50 genes identified low-risk and high-risk stage I lung adenocarcinomas, which differed significantly with respect to survival. This risk index was then validated using an independent sample of lung adenocarcinomas that predicted high-and low-risk groups. This index included genes not previously associated with survival. The identification of a set of genes that predict survival in early-stage lung adenocarcinoma allows delineation of a high-risk group that may benefit from adjuvant therapy.